Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Proteomics International Laboratories Ltd. (PIQ.AX)
Perth, WA, AU
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.57% | -10.00% | -42.55% | -60.29% | -66.67% | -79.39% | -67.86% | -86.08% | -88.66% | -42.55% | -32.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+7.7% Q4'25: -34.0% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-7.1% Q4'25: -19.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-1,043.9% Q4'25: -841.9% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%-1,105.7% Q4'25: -1,828.3% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%-480.9% Q4'25: -11,643.2% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%+18.8% Q4'25: +33.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×-0.03× Q4'25: -0.03× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.49M
est: 3.10M (-52.0%)
|
730.3K
est: 3.65M (-80.0%)
|
892.1K
est: 2.80M (-68.1%)
|
960.4K
est: 3.80M (-74.7%)
|
4.30M
4.30M – 4.30M
+13.2% YoY
|
5.90M
5.90M – 5.90M
+37.2% YoY
|
113.30M
113.30M – 113.30M
+1,820.3% YoY
|
| EBITDA |
-4.56M
est: -3.10M (-47.1%)
|
-7.55M
est: -3.65M (-106.9%)
|
-8.40M
est: -2.80M (-199.9%)
|
-10.00M
est: -3.80M (-163.1%)
|
-4.30M
-4.30M – -4.30M
-13.2% YoY
|
-5.90M
-5.90M – -5.90M
-37.2% YoY
|
-113.30M
-113.30M – -113.30M
-1,820.3% YoY
|
| EBIT |
-4.97M
est: -3.10M (-60.4%)
|
-8.82M
est: -3.65M (-141.5%)
|
-9.12M
est: -2.80M (-225.9%)
|
-10.62M
est: -3.80M (-179.4%)
|
-4.30M
-4.30M – -4.30M
-13.2% YoY
|
-5.90M
-5.90M – -5.90M
-37.2% YoY
|
-113.30M
-113.30M – -113.30M
-1,820.3% YoY
|
| Net Income |
-4.97M
est: -4.93M (-0.8%)
|
-6.23M
est: -6.28M (+0.7%)
|
-6.38M
est: -8.37M (+23.9%)
|
-8.11M
est: -7.33M (-10.7%)
|
-6.28M
-6.28M – -6.28M
+14.3% YoY
|
-5.83M
-5.83M – -5.83M
+7.1% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
4.48M
est: 12.77M (-64.9%)
|
5.11M
est: 15.04M (-66.0%)
|
1.72M
est: 11.53M (-85.1%)
|
6.17M
est: 15.65M (-60.6%)
|
17.71M
17.71M – 17.71M
+13.2% YoY
|
24.30M
24.30M – 24.30M
+37.2% YoY
|
466.74M
466.74M – 466.74M
+1,820.3% YoY
|
| EPS |
-0.05
est: -0.03 (-42.7%)
|
-0.05
est: -0.04 (-27.4%)
|
-0.05
est: -0.06 (+9.5%)
|
-0.05
est: -0.05 (-10.8%)
|
-0.04
-0.04 – -0.04
+14.3% YoY
|
-0.04
-0.04 – -0.04
+7.1% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jacqueline Gray | Head of Corporate Development | 291.4K | female |
| Phillip Prather | Chief Commercialisation Officer | 240.0K | male |
| Kirsten Peters | Head of Clinical Studies | — | — |
| Scott Bringans | Head of Research | — | — |
| Timothy Luscombe | CFO & Company Secretary | — | male |
| Pearl Tan | Head of Product Development | — | — |
| John Chuck Morrison | Head of Business Development | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PIQ.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
